KKR healthcare vet Jim Momtazee jump starts a new investment firm; Bayer signs up a top China biotech player to $645M deal
A year after Jim Momtazee stepped out of his lead role in charge of healthcare for private equity giant KKR, it’s time for the big …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
